TD Asset Management Inc Buys 27,592 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

TD Asset Management Inc increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 6.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 489,940 shares of the biopharmaceutical company’s stock after acquiring an additional 27,592 shares during the quarter. TD Asset Management Inc owned about 0.39% of Alnylam Pharmaceuticals worth $119,055,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Allspring Global Investments Holdings LLC increased its position in Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 143 shares during the period. Altitude Crest Partners Inc. bought a new position in Alnylam Pharmaceuticals during the first quarter worth $30,000. V Square Quantitative Management LLC bought a new position in Alnylam Pharmaceuticals during the fourth quarter worth $52,000. Benjamin F. Edwards & Company Inc. bought a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $71,000. Finally, GAMMA Investing LLC increased its holdings in Alnylam Pharmaceuticals by 97.2% in the 2nd quarter. GAMMA Investing LLC now owns 416 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 205 shares during the period. Institutional investors own 92.97% of the company’s stock.

Insider Activity

In other news, Director David E. I. Pyott sold 32,450 shares of the company’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $220.69, for a total value of $7,161,390.50. Following the completion of the sale, the director now directly owns 136 shares of the company’s stock, valued at approximately $30,013.84. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CEO Yvonne Greenstreet sold 15,000 shares of the company’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at approximately $20,563,480. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director David E. I. Pyott sold 32,450 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $220.69, for a total value of $7,161,390.50. Following the sale, the director now directly owns 136 shares of the company’s stock, valued at $30,013.84. The disclosure for this sale can be found here. Insiders sold a total of 103,148 shares of company stock valued at $25,658,824 in the last ninety days. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Trading Down 0.7 %

Alnylam Pharmaceuticals stock opened at $251.48 on Friday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $287.55. The company has a market cap of $31.81 billion, a PE ratio of -93.84 and a beta of 0.37. The company’s 50-day moving average is $257.28 and its two-hundred day moving average is $190.29.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million for the quarter, compared to analyst estimates of $447.22 million. During the same quarter in the previous year, the company posted ($2.21) earnings per share. The business’s revenue for the quarter was up 107.0% on a year-over-year basis. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.82 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ALNY shares. Royal Bank of Canada reissued an “outperform” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday. Wells Fargo & Company boosted their target price on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a research note on Friday, August 2nd. Cantor Fitzgerald boosted their target price on shares of Alnylam Pharmaceuticals from $150.00 to $220.00 and gave the company a “neutral” rating in a research note on Monday, July 22nd. Barclays boosted their target price on shares of Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, HC Wainwright restated a “buy” rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, August 30th. Seven equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $279.14.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.